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We have previously used Aspergillus nidulans as a
fungal model for human phenylalanine catabolism. This
model was crucial for our characterization of the human
gene involved in alcaptonuria. We use here an identical
approach to characterize at the cDNA level the human
gene for maleylacetoacetate isomerase (MAAI, EC
5.2.1.2), the only as yet unidentified structural gene of
the phenylalanine catabolic pathway.
We report here the first characterization of a gene
encoding a MAAI enzyme from any organism, the A.
nidulans maiA gene. maiA disruption prevents growth
on phenylalanine (Phe) and phenylacetate and results
in the absence of MAAI activity in vitro and Phe toxicity.
The MaiA protein shows strong amino acid sequence
identity to glutathione S-transferases and has MAAI ac-
tivity when expressed in Escherichia coli. maiA is clus-
tered with fahA and hmgA, the genes encoding the two
other enzymes of the common part of the Phe/phenyla-
cetate pathways.
Based on the high amino acid sequence conservation
existing between other homologous A. nidulans and hu-
man enzymes of this pathway, we used the MaiA se-
quence in data base searches to identify human ex-
pressed sequence tags encoding its putative
homologues. Four such cDNAs were sequenced and
shown to be encoded by the same gene. They encode a
protein with 45% sequence identity to MaiA, which
showed MAAI activity when expressed in E. coli.
Human MAAI deficiency would presumably cause ty-
rosinemia that would be characterized by the absence of
succinylacetone, the diagnostic compound resulting
from fumarylacetoacetate hydrolase deficiency in hu-
mans and fungi. Culture supernatants of an A. nidulans
strain disrupted for maiA are succinylacetone-negative
but specifically contain cis and/or trans isomers of 2,4-
dioxohept-2-enoic acid. We suggest that this com-
pound(s) might be diagnostic for human MAAI
deficiency.
The catabolism of phenylalanine and tyrosine in humans is
both of intrinsic and clinical interest. The enzymatic steps of
this pathway were definitively established in the ’50s by the
work of Knox and colleagues (see Fig. 1A; Ref. 1). However, two
of its structural genes remained uncharacterized. We recently
used a novel approach based on the development of a fungal
model to characterize one of them (2–4). Here we report our
successful application of this approach to the characterization
of the other and address by reverse genetics the consequences
of the corresponding enzyme deficiency in our model organism.
An enzyme deficiency in any of the steps of this pathway
causes in humans a known metabolic disease. For example, a
deficiency in phenylalanine hydroxylase causes phenylketonu-
ria (reviewed by Scriver et al. (5)). Enzyme deficiencies in four
other steps (those labeled as II, III, and VI in Fig. 1A) cause
different hypertyrosinemias (reviewed by Mitchell et al. (6)),
and absence of homogentisate dioxygenase (IV, see Fig. 1A)
causes alkaptonuria (4, 7). Although the historical interest in
the later is notable as it enabled Archibald Garrod to coin the
term of “inborn error of metabolism” (8, 9), the gene had not
been characterized until recently (3, 4, 10). Crucial for the
isolation and characterization of this gene was our establish-
ment of a fungal model for human phenylalanine catabolism
based on the filamentous ascomycete Aspergillus nidulans (2).
We cloned its homogentisate dioxygenase gene (the first gene
encoding this enzyme identified for any organism) and used its
derived amino acid sequence as a probe to identify in similarity
searches of the human expressed sequence, tag data base
(EST)1 cDNAs encoding its human homologue (3).
Type 1 hereditary tyrosinemia (HT1, hepatorenal tyrosine-
mia, McKusick 276700) is the most severe disease in human
Phe catabolism, affecting liver, kidney, and peripheral nerves.
HT1 patients surviving infancy develop chronic liver disease
with a high incidence of hepatocellular carcinoma (6). HT1
results from fumarylacetoacetate hydrolase (FAAH) deficiency
(11). It is generally accepted that fumarylacetoacetate and its
spontaneous reaction product, succinylacetone (the diagnostic
compound of the disease), are toxic due to their considerable
reactivity with key cellular molecules (6, 11), and fumarylac-
etoacetate has been shown to be mutagenic in Chinese hamster
cells (12). In agreement with this, growth of an A. nidulans
strain disrupted for the FAAH-encoding gene is prevented by
phenylalanine even in the presence of an alternative carbon
source (2). succinylacetone is accumulated in culture superna-
tants of this strain, illustrating the equivalent consequences of
a FAAH deficiency in humans and A. nidulans (2).
The clinical consequences of a MAAI (MAAI, EC 5.2.1.2; step
V in Fig. 1A) deficiency in humans are largely unknown. It is
predicted that this deficiency should also lead to HT1, as ma-
leylacetoacetate has similar reactivity to fumarylacetoacetate
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should not result in the presence of succinylacetone in plasma
and urine, as the latter compound is likely to be formed from
succinylacetoacetate resulting from in vivo reduction of maleyl
and fumarylacetoacetate (6, 11). Succinylacetoacetate is effi-
ciently degraded by FAAH (1), and its hydrolysis would prevent
succinylacetoacetone formation. Only one such succinylac-
etone-negative patient showing type 1 tyrosinemia with non-
detectable levels of MAAI but normal levels of FAAH in liver
has been described (14).
Mammalian MAAI has been little studied since its original
characterization (1, 15, 16), possibly due, among other possible
reasons, to the instability of the substrate (6). The gene encod-
ing MAAI has not been cloned from any organism, and it is
therefore the only structural gene of the Phe/Tyr degradation
pathway that remains uncharacterized, precluding the analy-
sis of the molecular basis of succinylacetone-negative type I
tyrosinemia. Here we successfully use our fungal model to
identify cDNAs encoding human MAAI. The liver enzyme re-
quires glutathione (1, 15, 16) as does the equivalent bacterial
enzyme that has been purified to homogeneity (17). Our char-
acterization of fungal and human MAAI cDNAs revealed
strong amino acid sequence identity of their derived protein
sequences to glutathione S-transferases, in agreement with the
proposed mechanism of the isomerization (18). We also extend
the work of Edwards and Knox (16) and demonstrate MAAI
activity by an in vitro complementation assay using extracts
from a recombinant fungal strain deficient for MAAI. Notably,
we detected no succinylacetone in culture supernatants of this
strain.
EXPERIMENTAL PROCEDURES
Fungal Strains, Media, and Growth Conditions—A. nidulans strains
carried markers in standard use (19). A biA1 strain was used as a
source of cDNA and wild type protein extracts. The biA1, methG1,
DfahA strain has been described (2). A biA1, methG1 strain was used as
the wild type in growth tests. Standard media for A. nidulans (20) were
used for strain maintenance, growth tests, and transformation. Culture
conditions inducing high levels of expression of the fahA/maiA/hmgA
genes, which were routinely used to grow mycelia for protein extraction,
have been described (21).
Identification of the A. nidulans maiA Gene—Genomic maiA se-
quences were identified by Southern analysis of DNA from lEMBL4
clones carrying the fahA and hmgA genes, using a subtracted cDNA
probe representing genes induced by phenylacetate (“plus” probe) and a
cDNA probe from glucose-grown mycelia (“minus” probe). A 2.5-kb
EcoRI fragment contiguous to the fahA transcription unit (see Fig. 1B)
showed strong differential hybridization to the plus probe. In addition,
cDNA library screening using the F2 fragment (see Fig. 1A) resulted in
the isolation, in addition to fahA cDNA clones, of a second class of cDNA
clones representing maiA transcripts. The cDNA library enriched in
transcripts induced by phenylacetate and the subtracted plus cDNA
probe have been described (2, 3). The A. nidulans genomic library was
a standard lEMBL4 library constructed from the wild type strain. RNA
isolation and Northern analysis followed (22). Equal loading of the
different samples was confirmed using an actin probe.
Disruption of the maiA Gene—Transformation followed Tilburn et al.
(23). For disruption of maiA we used a 4.2-kb linear DNA fragment in
which the sequence between maiA codons 140–226 had been replaced
by a 3.2-kb XbaI fragment carrying argB1. A genomic fragment carry-
ing maiA sequences from an XbaI site at position 2133 (relative to the
initiation codon) to an XhoI site at position 1655 (relative to the stop
codon) was subcloned in pBS-SK1 (Stratagene). Substitution of an
internal 0.26-kb SalI-EcoRI fragment by the above 3.2-kb A. nidulans
genomic fragment (whose XbaI ends had been previously converted to
EcoRI and XhoI) removed maiA sequences between codons 140 and 226
to yield pBS-DMAI. The transforming fragment was isolated from this
plasmid after digestion with XbaI and XhoI.
Enzyme Assays—Maleylacetoacetate, which is not commercially
available, was synthesized enzymatically from homogentisate (1, 15)
using homogentisate dioxygenase from A. nidulans extracts or from
Escherichia coli cells overexpressing the human enzyme. The procedure
used to obtain mycelial protein extracts from DfahA, DmaiA, and wild
type A. nidulans strains and the conditions for the homogentisate
dioxygenase reaction have been described (21). For in vitro complemen-
tation assays, the initial homogentisate concentration was 100–125 mM.
Maleylacetoacetate formation was monitored spectrophotometrically at
330 nm. When the reaction reached a plateau (with usually more than
80% of the substrate converted to maleylacetoacetate), 150 mM reduced
glutathione was added to allow the MAAI-dependent isomerization of
maleylacetoacetate to fumarylacetoacetate (1, 16), which is then a sub-
strate for FAAH. Complementation of DmaiA extracts was used to
detect MAAI activity in crude lysates of E. coli cells overexpressing
fungal or human MAAI, as described in the corresponding figure
legends.
Absorption Spectra of Intermediates—Maleylacetoacetate was syn-
thesized in separate reactions using 250–500 mM substrate and an
excess of recombinant human HGO. When the reactions reached a
plateau, they were stopped and deproteinized after the addition of 0.1
vol of 10% metaphosphoric acid, incubation for 10 min in ice, and
centrifugation at 13,000 3 g for 10 min. The supernatants were neu-
tralized with KOH to pH 7.5–8 and immediately used in in vitro
reactions in the presence of wild type or mutant A. nidulans protein
extracts. These reaction mixtures were essentially as for homogentisate
dioxygenase but contained GSH as a cofactor for MAAI. Reactions were
carried out for 15 min at room temperature, deproteinized with meta-
phosphoric acid, and neutralized with KOH as above. The absorption
spectra of these samples were determined and compared with those of
duplicate reaction mixtures for which the final neutralization step was
omitted.
Overexpression of Proteins in E. coli—High levels of protein expres-
sion were achieved using the pD1 vector (a gift of E. Espeso). This is a
modified pET19b (Novagen) derivative that was engineered to intro-
duce a single BamHI site allowing in-frame fusion of the desired coding
region to an N-terminal His tag. Details of this vector will be described
elsewhere. Proteins overexpressed in this system carry the sequence
MGHHHHHHHHHHSSGHIDDDDKHMGS at their amino termini.
The MaiA coding region was amplified using the following pair of
primers (underlined sequences add or modify restriction sites): 59-CGG-
GATCCCCCGCACCGGTCAAGATCTC-39 (upper) and 59-CGGAAT-
TCAACACCTAAATTCCGTTGGTG-39 (lower). The fusion protein con-
tains the complete MaiA sequence with four further extra residues
(PAPL) between the above N-terminal tag and the MaiA initiation
methionine. The corresponding recombinant plasmid was denoted
pD1::MaiA. The human MAAI coding region was amplified using EST
265310 (59) as template and primers 59-CAGGGATCCAAGCCCATC-
CTCTATTCC-39 (upper) and 59-CAGGAATTCGGAGCTAGGCCCTC-39
(lower). The recombinant gene fused the above N-terminal tag to resi-
dues 5–216 of the protein. The corresponding plasmid was denoted
pD1::HSMAAI. A pD1::HSHGO plasmid (a gift from M. C. Este´banez),
driving high level expression of human HGO, will be described
elsewhere.
Recombinant plasmids were selected in E. coli DH1, purified, and
transformed into E. coli BLB21(DE3)pLysS. Primary transformants
were selected on LB plates containing ampicillin (100 mg/ml) and chlor-
amphenicol (35 mg/ml) and directly used to inoculate LB liquid cultures
that were grown at 37 °C until A600 reached 0.8–0.9 units. Expression
of T7 RNA polymerase was induced after the addition of 0.4 mM isopro-
pyl-1-thio-b-D-galactopyranoside and further incubation for 2.5 h. 0.5
ml samples were taken before and after induction, and bacteria were
collected by centrifugation and resuspended in SDS-polyacrylamide gel
electrophoresis loading buffer. Samples were boiled for 3 min before
loading appropriate aliquots onto a 12% SDS-polyacrylamide gel along-
side Bio-Rad wide-range protein markers. Proteins were detected by
Coomassie staining.
For preparation of protein extracts, bacteria from a 50-ml culture
were collected by centrifugation, washed in 100 mM potassium phos-
phate buffer, pH 7.0, resuspended in 4 ml of the same buffer, and lysed
by sonication. Lysates were clarified by centrifugation at 10,000 rpm
and 4 °C for 20 min in an SS34 rotor. Protein concentrations were
estimated by the Bradford assay (24).
GC-MS Analysis of Culture Filtrates—Fungal mycelia pregrown on
0.6% glucose (w/v) as the sole carbon source were transferred to appro-
priately supplemented minimal medium with 20 mM phenylacetate as
the sole carbon source (see Ref. 21) and incubated for 20 h at 37 °C.
Culture filtrates were ether-extracted and derivatized with bis(trimeth-
ylsilyl)trifluoroacetamide as described (2). TMS derivatives were ana-
lyzed by GC-MS in a fused silica capillary column SBP-1 (30 m 3 0.25
mm; 0.2-mm film thickness) with a temperature program from 80 to
280 °C (4 °C/min), and a Q-MASS (Perkin-Elmer) mass detector. Iden-
tification of peaks was carried out by comparison of sample spectra with
reference spectra from the NIST/EPA/NIH mass spectral data base.
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DNA Sequencing—Genes and cDNAs were sequenced using a Dye
Terminator Cycle sequencing kit (Perkin-Elmer) and Taq FS DNA
polymerase with universal and custom primers. Sequencing reactions
were resolved on an ABI Prism 377 automatic sequencer and analyzed
with the ABI analysis software (Version 3.1). Genomic and cDNA ver-
sions of maiA and human EST cDNA clones 265310 (59), 290219 (59),
683733 (59), and 52677(59) encoding human MAAI were completely
sequenced in both strands. cDNA clones of the IMAGE consortium (25)
were purchased from Genome Systems Inc., (St. Louis, MO).2
RESULTS
A Cluster of Three Genes Encoding Enzymes of the Common
Part of the A. nidulans PhAc/Phe Catabolic Pathway—The
ascomycete fungus A. nidulans can use either Phe or PhAc as
sole carbon source (Fig. 1A). Both compounds were catabolized
to homogentisate, which was then converted to fumarate and
acetoacetate through the action of three enzyme activities,
HGO, MAAI, and FAAH. We have previously reported that the
A. nidulans fahA and hmgA genes encoding FAAH and HGO,
respectively, are closely linked and divergently transcribed
from a 414-base pair intergenic region. fahA and hmgA gene
transcription is strongly inducible by PhAc (or its structural
relatives) or Phe and partially repressible by glucose. Neither
of these genes is expressed on glucose as the sole carbon source.
No gene encoding MAAI has yet been characterized from any
organism. Southern blot hybridization of lEMBL4 phage
clones carrying the fahA and hmgA genes with a substracted
cDNA probe representing transcripts induced by PhAc revealed
the presence of a third linked gene strongly hybridizing to this
probe. As fahA and hmgA, this third gene, designated maiA,
was not expressed on glucose. Clustering of genes encoding
activities of the same catabolic pathway is not unusual in A.
nidulans. Genomic and cDNA nucleotide sequencing of the
region encoding this new transcript confirmed the presence of a
third gene 39 from fahA, transcribed in a tail-to-tail orientation
(Fig. 1B). The transcribed region contains an intron-less ORF
encoding a putative 230-residue polypeptide (Fig. 2) whose stop
codon is 486 base pairs downstream from that of fahA. The
nucleotide sequence of this three-gene cluster has been submit-
ted to the DDBJ/EMBL/GenBankTM data bases under acces-
sion number AJ001836.
A. nidulans maiA Encodes Maleylacetoacetate Isomerase—
Data base searches revealed that the predicted product of maiA
shows strong amino acid sequence identity to glutathione S-
transferases. For example, FASTA searches of the Swiss-Prot
data base revealed that among the 30 protein sequences show-
ing the highest alignment scores, 27 were glutathione S-trans-
ferases (data not shown). Similar results were obtained after
searching the conceptual translation of EMBL 1 GenBankTM
nucleotide sequence data bases with TBLASTN. The highest
FASTA score corresponded to glutathione S-transferase 1 from
Diantus caryophyllus, which showed 33.3% identity to MaiA in
a 228-amino acid overlap including the complete sequence of
both proteins (data not shown). The deduced molecular mass
for MaiA (25,129 Da) is similar to the 25-kDa size of glutathi-
one S-transferases.
Northern analysis showed that, as determined for fahA and
hmgA, transcription of maiA was induced by either Phe or
PhAc and was absent on glucose or gluconeogenic carbon
sources (Fig. 3), strongly suggesting that maiA was a gene for
Phe/PhAc catabolism and that its clustering with fahA and
hmgA reflected its involvement in the same catabolic pathway.
The only as yet unidentified gene encoding an enzyme essential
for both Phe and PhAc catabolism is that encoding MAAI. The
likely mechanism of this enzyme involves transfer of enzyme-
bound GSH to C2 of maleylacetoacetate (26). Therefore, all the
above data indicated that maiA might encode A. nidulans
MAAI.
To confirm this, we replaced by transformation the wild type
maiA gene by a mutant version in which the sequence encoding
MaiA residues 140–226 had been substituted by a genomic
DNA fragment containing the argB1 gene (Fig. 4A). Transfor-
mants were selected in an argB2 background for arginine-
2 Details of EST libraries may be found in http://www-bio.llnl.gov/
bbrp/image/humlib_info.html.
FIG. 1. The phenylalanine/phenylacetate degradation pathway. A, enzymes required for PhAc degradation to homogentisate are only
present in A. nidulans. Enzymes for Phe catabolism to fumarate and acetoacetate (1) are present both in humans and A. nidulans. Enzymatic steps
in the Phe pathway are denoted with roman numbers. The abbreviations for the enzymes used throughout this work are also shown. Single enzyme
deficiencies cause the following diseases: I, phenylketonuria; II, type II (oculocutaneous) tyrosinemia; III, type III tyrosinemia; IV, alkaptonuria;
V, (presumably) a variant of type 1 tyrosinemia; VI, type 1 tyrosinemia. B, the A. nidulans cluster for the three genes encoding the common part
of the Phe/PhAc degradation pathway. Contiguous genomic DNA fragments (F1–F4) and their sizes are indicated. hmgA encodes HGO (3), fahA
encodes FAAH (2), and maiA encodes MAAI (this work). Arrows indicate the direction of transcription. E, EcoRI.
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independent growth and purified by repeated streaking of con-
idiospores on minimal medium lacking arginine. Two
independent transformants showing the expected maiA re-
placement were selected after Southern analysis. Both showed
an identical phenotype, being unable to grow on either phen-
ylacetate or phenylalanine as the sole carbon source. This
confirmed that maiA is a gene of the common part of the
Phe/PhAc pathways. MAAI assays were carried out with pro-
tein extracts from mycelia of the disrupted strains grown on
glucose and transferred to PhAc, which showed them to be
deficient for MAAI activity (Fig. 5). By contrast, these extracts
showed normal levels of either FAAH or HGO (data not shown).
Maleylacetoacetate can be synthesized in vitro by the homogen-
tisate dioxygenase activity present in mycelial extracts from
the wild type strain or from either a mutant DfahA strain
(lacking FAAH (2)) or a mutant DmaiA strain (presumably
lacking MAAI) and detected by its absorption at 330 nm (1, 15,
16). In the absence of GSH, an obligate cofactor of MAAI,
maleylacetoacetate is not isomerized to fumarylacetoacetate,
thereby providing an enzymatic method to obtain the isomer-
ase substrate (15, 16). On addition of GSH, wild type extracts
catalyze the isomerization of maleylacetoacetate to fumarylac-
etoacetate and the conversion of the latter to fumarate and
acetoacetate. As neither of these two latter compounds shows
the characteristic absorption of diketoacids in the near ultra-
violet region, this coupled enzyme reaction can be monitored by
the decrease of A330 (see Fig. 5; Refs. 15 and 16). Neither
mutant extract alone would catalyze a decrease in A330, as
maleylacetoacetate (which would accumulate with the DmaiA
extract; see below) and fumarylacetoacetate (which accumu-
FIG. 3. Northern analysis of maiA transcript levels. Cells were
grown on minimal medium with 0.3% (w/v) glucose as sole carbon
source for 16 h at 37 °C and transferred to media with the indicated
carbon sources. These secondary cultures were incubated for a further
1 h at 37 °C. Mycelia were then harvested and used to isolate RNA. The
probe was a cDNA clone insert containing the complete maiA ORF. -C
indicates no carbon source added.
FIG. 2. Nucleotide and deduced
amino acid sequence of A. nidulans
maiA. The genomic sequence is shown
here. The 59 limit of the cDNA clone show-
ing the longest 59-UTR is shown with an
arrow. Sequence downstream from the
translation stop codon is shown up to the
limit of the cDNA clone carrying the long-
est 39-UTR sequence. cDNA sequencing
revealed the absence of introns. The se-
quence has been submitted to DDBJ/
EMBL/GenBankTM data bases under ac-
cession number AJ001837.
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lates with the DfahA extract) have similar e330 at neutral pH
(15). By contrast, a mixture of the two mutant extracts should
provide both the isomerase and the hydrolase, and their cou-
pled action should result in conversion of maleylacetoacetate to
fumarate and acetoacetate. Fig. 5 shows that these predictions
were fulfilled by mutant extracts. We concluded that the DfahA
extract provided an activity required for catabolism of maley-
lacetoacetate that was missing in the DmaiA extract. Sequen-
tial addition of extracts instead of their simultaneous mixing
resulted in substantially identical results (data not shown).
Taken in the context of the enzymes known to be required for
homogentisate degradation (Fig. 1A), these data further indi-
cated that MaiA is a fungal MAAI.
In contrast to fumarylacetoacetate, which shows a similar
e330 at both pH 1 and pH 7.5, maleylacetoacetate shows a
10-fold lower e330 at pH 1 than at pH 7.5 (15). Therefore, a fall
in A330 upon acidification of the homogentisate dioxygenase
reaction product is diagnostic of maleylacetoacetate (Fig. 6, A
and B; it should be noted that the absorption maximum for the
above compounds is at approximately 320 nm (see also Ref. 15).
This was used to confirm its accumulation with the DmaiA but
not with the DfahA extract. Maleylacetoacetate was prepared
using recombinant human HGO expressed in E. coli as de-
scribed under “Experimental Procedures” and incubated in the
presence of the wild type or mutant extracts and GSH. Incu-
bation with the wild type extract resulted in the disappearance
of compounds absorbing in the near ultraviolet region at either
acidic or neutral pH (Fig. 6, D and H). By contrast, the char-
acteristic absorption of maleylacetoacetate at neutral but not
at acidic pH was still detectable upon incubation with the
DmaiA extract (Fig. 6, B and F). Incubation of the substrate
with the DfahA extract (which contains the isomerase but not
the hydrolase) produced a compound (fumarylacetoacetate)
showing strong absorbance in the above region both at acidic
and neutral pH (Fig. 6, C and G).
FIG. 4. Disruption of maiA. A, the wild type maiA gene was re-
placed by a mutant version by transformation with a linear XbaI-XhoI
A. nidulans genomic DNA fragment in which maiA codons 140–226
have been replaced by a 3.2-kb fragment carrying the argB1 gene.
Transformants carrying the integration event shown were identified by
Southern analysis. Xb, XbaI; S, SalI; E, EcoRI; Xh, XhoI; (S), a de-
stroyed SalI site. Dashed box, the maiA coding region; gray box, the
3.2-kb argB1 fragment. B, disruption of maiA results in Phe toxicity.
Two independent clones (right and left colonies) carrying the above gene
replacement were inoculated on minimal medium with lactose 0.05%
(w/v) in the absence (left panel) or in the presence (right panel) of 25 mM
Phe. A wild type (top) and a DfahA strain (bottom) were inoculated as
controls. Plates were incubated at 37 °C for 96 h.
FIG. 5. Absence of MAAI activity in extracts of the A. nidulans
strain deleted for the maiA gene. Large panel, equal amounts of
protein extracts from the indicated mutant A. nidulans strains grown
under inducing conditions were used either alone or in combination to
synthesize maleylacetoacetate from homogentisate. When A330
(O.D.330) did not increase further, GSH (an obligate cofactor of MAAI)
was added at 0.1 mM. A decrease in A330 is indicative of maleylaceto-
acetate conversion to fumarate and acetoacetate through the coupled
action of MAAI and FAAH. No decrease indicates that one of these
enzyme activities is lacking. The smaller panel shows control reactions
carried out with a wild type extract. GSH was added at the times
indicated with an arrow.
FIG. 6. Absorption spectra of the compounds accumulated af-
ter in vitro incubation of maleylacetoacetate with mutant A.
nidulans protein extracts. Maleylacetoacetate (CONTROL spectra)
was synthesized using bacterially expressed HGO and incubated in the
presence of equivalent amounts of the indicated protein extracts. Reac-
tions were carried out for 15 min at 23 °C as described under “Experi-
mental Procedures.” A–D, acid pH; E–H, neutral pH; O.D., absorbance.
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Expression of A. nidulans MaiA in E. coli—To definitively
establish that MaiA is A. nidulans MAAI, we expressed the
polypeptide as a fusion protein (see “Experimental Proce-
dures”) in E. coli under the control of a T7 RNA polymerase-
dependent promoter. Promoter induction resulted in the syn-
thesis of a markedly abundant 32-kDa protein that was absent
from extracts of induced cells carrying the expression vector
with no insert. This protein, whose electrophoretic mobility
was roughly consistent with the Mr predicted for the MaiA
fusion protein, remained soluble upon clarification of the cell
lysate (data not shown). In vitro complementation of A. nidu-
lans DmaiA and DfahA protein extracts described above sug-
gested the use of DmaiA extracts in a coupled enzyme assay for
MAAI. DmaiA extracts are unable to transform homogentisate
to fumarate and acetoacetate unless supplemented with MAAI
enzyme. Fig. 7 shows that an extract from E. coli cells overex-
pressing MaiA complemented this MAAI deficiency in vitro.
The coupled action of bacterially expressed MAAI and endoge-
nous A. nidulans FAAH resulted in the efficient degradation of
maleylacetoacetate. This coupled degradation obligately re-
quired GSH and did not occur with an extract of E. coli cells
carrying the expression vector with no insert (Fig. 7).
In addition, we synthesized maleylacetoacetate using recom-
binant human homogentisate dioxygenase. It showed the diag-
nostic high absorbance in the near ultraviolet region under
neutral but not under acidic pH conditions (see above). Incu-
bation of this compound in the presence of the E. coli extract
overexpressing MaiA and GSH resulted in its conversion to
fumarylacetoacetate, as shown by the characteristic high ab-
sorbance of the latter in this region both under acidic and
neutral pH conditions. This conversion did not take place when
extracts overexpressing the protein were substituted by control
extracts (data not shown). As a whole, these results provide
formal evidence that A. nidulans maiA encodes MAAI.
Analysis of A. nidulans Culture Supernatants for Diagnostic
Compounds of MAAI Deficiency—An A. nidulans strain dis-
rupted for the gene encoding FAAH accumulates succinylac-
etone, the diagnostic compound for HT1 (caused by FAAH
deficiency) in the urine of human patients. Growth of a DfahA
strain on lactose (which is unaffected by the mutation) is
strongly inhibited by Phe ((2); see Fig. 4B). Phe toxicity in this
mutant background is due to fumarylacetoacetate and/or its
spontaneous reaction product, succinylacetone, which accumu-
late(s) as a result of the enzyme deficiency. Notably, growth of
a strain disrupted for maiA was also inhibited by Phe (Fig. 4B),
although clearly to a lesser extent than that of the DfahA
strain, strongly suggesting that different catabolites with dis-
tinct toxicities accumulate in each disrupted strain (but see
“Discussion”).
No specific diagnostic method is available for a deficiency in
human MAAI. We therefore investigated by GC-MS the com-
pounds accumulated in a culture supernatant of our DmaiA
strain transferred to phenylacetate and detected four peaks
almost certainly corresponding to cis and/or trans isomers of
4,6-dioxohept-2-enoic acid (Fig. 8), as shown by comparison of
their mass spectra with those for the above compound(s) de-
posited in the data bases. These four peaks presumably repre-
sent different TMS derivatives of the above compound(s) (see
legend to Fig. 8). Neither of the two possible cis-trans isomers
of 4,6-dioxohept-2-enoic acid, maleylacetone and fumarylac-
etone, had been detected in culture supernatants of either the
wild type or a DfahA strain (2), strongly suggesting that its
(their) presence specifically results from the DmaiA mutation.
Notably, no peaks corresponding to succinylacetone were
detected.
Identification of Human EST Clones Encoding Homologues
of A. nidulans MaiA—We next used the fungal MaiA amino
acid sequence to screen the EST data bases for human and
murine ESTs encoding putative MaiA homologues, in analogy
with the protocol already established for the AKU gene (3, 4).
BLAST searches identified a number of these human ESTs.
The 10 highest scores were obtained with the derived amino
acid sequences of the following human ESTs (with the source of
RNA for each EST cDNA clone in parentheses): 683733 (ger-
minal B cells), 290219 (multiple sclerosis), 290775 and 265310
(melanocytes), 52677 (infant brain), 156401 (breast), 309975
(senescent fibroblasts), 240726 and 246479 (fetal liver/spleen),
and 66e04 (skeletal muscle). These (partial) amino acid se-
quences showed more than 40% identity to that of A. nidulans
MaiA, strongly suggesting that they represent its human ho-
mologue(s). The fact that only minor differences in the se-
quence (presumably resulting from automated sequencing er-
rors) were found between these derived human proteins
strongly suggests that all these cDNAs correspond to a single
gene. Tissue-specific expression of such a gene does not appear
to be as restricted as that of HGO (3, 4), and only two of the 10
cDNA clones represented liver transcripts (see above). In ad-
dition to the above human protein sequences, data base
searches detected MaiA homology to derived protein products
of mouse and Arabidopsis thaliana EST clones (not shown).
Molecular Characterization of Human cDNAs Encoding Ma-
leylacetoacetate Isomerase—We fully sequenced four of the
above ESTs. (Fig. 9A). Nucleotide sequencing showed that they
were indeed encoded by the same gene, despite the fact that
FIG. 7. MAAI activity of A. nidulans MaiA synthesized in E.
coli. An A. nidulans DmaiA extract (lacking MAAI, see Figs. 5 and 6)
was used in three identical, separate reactions to synthesize maleyla-
cetoacetate, which was monitored by its A330 (O.D.
330). When A330
showed no further increase, GSH (150 mM, small arrows) and protein
extracts (50 mg, large arrows) from control E. coli cells or from E. coli
cells overexpressing MaiA were added as indicated. Degradation of
maleylacetoacetate to fumarate and acetoacetate was monitored by the
decrease of A330 and required the addition of both bacterially expressed
MaiA and GSH.
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they had been isolated from different tissues. EST 265310 (59)
(melanocytes) is the longest of these cDNAs. It is 1155 base
pairs long (excluding the poly(A) tail) and contains a 216-codon
ORF whose derived protein product (Mr 24,083) shows 45%
identity in amino acid sequence to A. nidulans MAAI (Fig. 9B).
This represents nearly definitive evidence that this cDNA en-
codes a human MAAI (but see below). The complete nucleotide
sequence of this cDNA has been submitted to DDBJ/EMBL/
GenBankTM data bases (accession number AJ001838) The 39-
UTR of this transcript was remarkably long (400 nucleotides,
i.e. 30% of the transcript size). ESTs 290219 (59) (multiple
sclerosis lesions) and 683733 (59) (germinal B-cells) repre-
sented cDNAs incomplete at their 59 ends, starting at codons 18
and 49, respectively, of the human MAAI ORF. The precise site
of polyadenylation and the sequence of the 400-nucleotide 39-
UTR of EST 290219 were identical to those of the longest
cDNA. Polyadenylation of the 683733 cDNA occurred two nu-
cleotides upstream of the above site, but no other nucleotide
sequence difference was observed either in the 39-UTR or in the
coding region. Finally, we detected no differences between the
nucleotide sequences of EST 52677 (brain) and EST 265310 up
to position 1045, where the former is prematurely polyadeny-
lated as compared with the latter. This strongly suggests that
the 59 ends of these two transcripts represent a transcription
start site for the human MAAI gene.
To confirm that the ORF of these transcripts encodes a
human MAAI, the protein product encoded by the EST 265310
(59) ORF was overexpressed in E. coli as above. High levels of
a protein with the expected mobility for this polypeptide prod-
uct were detected by SDS-polyacrylamide gel electrophoresis
when recombinant E. coli cells in which its expression was
driven by a T7-polymerase promoter (see “Experimental Pro-
cedures”) were grown under inducing conditions (data not
shown) and were absent from these cells grown under nonin-
ducing conditions. Extracts from E. coli cells overexpressing
this protein showed strong maleylacetoacetate isomerase activ-
ity, as shown by its ability to complement an A. nidulans
extract deficient for the enzyme (Fig. 10). This strong MAAI
activity was dependent on the presence of GSH (not shown). By
contrast, control cells showed no MAAI activity. These results
establish that the product of the EST 265310 ORF (and, by
extension, of the above four cDNAs) is a human maleylaceto-
acetate isomerase.
DISCUSSION
We describe here the molecular characterization of maiA, a
gene encoding an enzyme of the common part of the A. nidulans
FIG. 8. GC-MS analysis of a culture
supernatant of the DmaiA strain.
Ether-extractable compounds were ana-
lyzed as TMS derivatives by GC-MS.
Identified peaks were assigned to a com-
pound by computer comparison of their
mass spectra with reference spectra of the
NIST/EPA/NIH mass spectra data base.
A selected portion of the chromatogram
including three peaks (denoted with ro-
man number I) that were identified as
di-TMS derivatives of 4,6-dioxohept-2-
enoic acid is shown at the bottom. Peaks
labeled with ? represent unidentified com-
pounds. Peak II, 2-hydroxyphenylacetate;
III, ethylvanilline (internal standard,
;0.2 mg); IV, 3-hydroxyphenylacetate; V,
possibly octadecenol. The mass spectra of
the major peak of 4,6-dioxohept-2-enoic
acid (di-TMS) (indicated with a filled ar-
rowhead in the chromatogram) is shown.
A fourth peak (not shown in this portion
of the chromatogram) was identified as
the tri-TMS derivative of 4,6-dioxohept-2-
enoic acid.
FIG. 9. Characterization of human MAAI cDNAs and derived
amino acid sequence of human MAAI. A, four EST cDNAs encoding
putative MaiA homologues were fully sequenced. The corresponding
four mRNAs appear to be transcribed from the same gene (see text for
details). The limits of these four cDNAs with respect to the human
MAAI coding region are shown. B, amino acid sequence of human MAAI
(HS) and its comparison to its fungal homologue (AN). The amino acid
sequence of the 216-residue-derived protein encoded by the EST 265310
(59) ORF (and the three other EST ORFs above) is shown compared with
that of A. nidulans MaiA (this work). Vertical bars indicate identity.
The alignment was carried out using BESTFIT (GCG package).
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phenylalanine/phenylacetate pathways and provide definitive
biochemical and genetic evidence that this gene encodes a
maleylacetoacetate isomerase. This paper represents the first
characterization of a gene encoding MAAI from any organism.
Compelling evidence for the above conclusion can be summa-
rized as follows: (i) maiA is clustered with fahA and hmgA, the
two other structural genes of this common part of the path-
ways; (ii) transcription of the gene is induced by phenylalanine
or phenylacetate as sole carbon sources; (iii) the deduced amino
acid sequence of its encoded protein shows identity to glutathi-
one S-transferases, as expected for a MAAI enzyme; (iv) dis-
ruption of the gene prevents growth on either Phe or phenyla-
cetate; (v) protein extracts from this disrupted strain convert
homogentisate to maleylacetoacetate but cannot catabolize this
compound further; (vi) mixing DmaiA and DfahA extracts re-
sults in reciprocal complementation of the corresponding en-
zyme deficiencies required for maleylacetoacetate catabolism
to fumarate and acetoacetate; (vi) expression of maiA in E. coli
results in bacterial protein extracts showing MAAI activity.
Two technical developments were crucial to obtaining some of
the above evidence. First, we used either recombinant HGO
enzyme (4) or fungal extracts showing high HGO activity (21)
to efficiently synthesize maleylacetoacetate. Second, we used a
complementation assay for MAAI based on a protein extract
from our A. nidulans strain deleted for maiA. This extract
converted homogentisate to fumarate and acetoacetate only
when supplied with GSH and a source of MAAI.
We next used the MaiA-derived sequence to identify human,
mouse, and plant ESTs encoding proteins showing high amino
acid sequence identity to A. nidulans MAAI. Four such human
cDNAs were fully sequenced and shown to encode a protein
with 45% identity to MaiA. Although they were isolated from
different tissues, these four cDNAs (and the other ESTs de-
tected in our searches) almost certainly represent transcripts of
the same gene. The protein encoded by this transcript(s) has
MAAI activity when expressed in E. coli. Our electronic screen-
ing of the human EST data base would suggest that expression
of this gene would be more ubiquitous than that of HGO, whose
expression is largely restricted to liver, kidney, colon, small
intestine, and prostate. This apparently less restricted pattern
of expression might be related to its ability to use other com-
pounds, in addition to maleylacetoacetate, as substrates (26),
which might suggest a detoxification function (6).
Our characterization of human MAAI cDNAs represents the
identification of the only as yet undescribed gene of the human
Phe catabolic pathway. These results further confirm the va-
lidity of our fungal metabolic model and open the possibility of
analyzing at the molecular level the predicted disease (a pos-
sible variant of HT1) resulting from MAAI deficiency. The
incidence of this inborn error of metabolism is presently un-
known, perhaps due to the absence of clear biochemical and/or
molecular diagnostic criteria. A single patient with a putative
MAAI deficiency has been reported in an abstract (14). Nota-
bly, this patient suffered from severe hepatorenal and brain
damage. Our results with the fungal model show that the
metabolite(s) accumulated as a result of a MAAI deficiency is
indeed toxic for Aspergillus, but their toxicity is detectably
lower than the toxicity of those accumulated as a result of a
FAAH deficiency. Jorquera and Tanguay (12) have reported
that, in contrast to fumarylacetoacetate, maleylacetoacetate
was not mutagenic in Chinese hamster cells. We have not yet
addressed if either of the above deficiencies is mutagenic in
Aspergillus.
We detected no succinylacetone in culture supernatants of
the A. nidulans DmaiA strain. This would be expected from the
presumed origin of succinylacetone from decarboxylation of
succinylacetoacetate, as normal levels of FAAH in this strain
would degrade the latter (1). Therefore, this absence of succi-
nylacetone might, at least in part, account for the lower Phe
toxicity found in an A. nidulans strain deficient for MAAI as
compared with a strain deficient for FAAH. Analysis of culture
filtrates of the A. nidulans DmaiA strain specifically detected
the presence of 4,6-dioxohept-2-enoic acid. This chemical struc-
ture would be consistent with maleylacetone (cis isomer) and/or
fumarylacetone (trans isomer). These isomers cannot be reli-
ably distinguished by the methodology used here. Taking into
account the remarkable similarities in the consequences of
equivalent metabolic blocks in human and fungal Phe catabo-
lism, we suggest cis and/or trans isomers of 4,6-dioxohept-2-
enoic acid as possible diagnostic compound(s) for MAAI defi-
ciency in humans.
Acknowledgments—We thank S. Rodrı´guez de Co´rdoba for critical
reading of the manuscript, an anonymous reviewer for his/her careful
checking of errors and useful suggestions, E. Reoyo for technical assist-
ance, and A. Hurtado, V. Mun˜oz, and M. Fontenla for artwork.
Note Added in Proof—An unpublished sequence recently submitted
to the GenBank™/EBI Data Bank with accession number U86529 and
described as a cDNA encoding a human glutathione transferase Zeta 1
is the same as our cDNA sequence for human maleylacetoacetate
isomerase.
REFERENCES
1. Knox, W. E. (1955) Methods Enzymol. 2, 287–300
2. Ferna´ndez-Can˜o´n, J. M., and Pen˜alva, M. A. (1995) Proc. Natl. Acad. Sci.
U. S. A. 92, 9132–9136
3. Ferna´ndez-Can˜o´n, J. M., and Pen˜alva, M. A. (1995) J. Biol. Chem. 270,
FIG. 10. The product of the human EST 265310 (5*) ORF has
MAAI activity. Detection of MAAI activity in cleared lysates of E. coli
cells that overexpressed the protein encoded by this ORF under the
control of a T7 polymerase-dependent promoter (see “Experimental
Procedures”). The assay for MAAI, based on complementation of an A.
nidulans DmaiA extract, was as in Fig. 7. The time points at which
reduced glutathione (150 mM) and protein extracts (;50 mg) were added
is indicated. Filled circles, a reaction to which a bacterial extract over-
expressing the product of the EST 265310 ORF was added. The levels of
expression achieved for this protein (not shown) were similar to those
for A. nidulans MaiA. Triangles, an extract from induced E. coli cells
carrying the expression vector with no insert. Open circles, a second,
negative control reaction in which an extract from a recombinant bac-
terial clone that showed no overexpression of the desired EST 265310
protein (as determined by SDS-polyacrylamide gel electrophoresis) was
added. O.D.330, A330.
Fungal and Human Genes for Maleylacetoacetate Isomerase336
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 18, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
21199–21205
4. Ferna´ndez-Can˜o´n, J. M., Granadino, B., Beltra´n-Balero de Bernabe´, D.,
Renedo, M., Ferna´ndez-Ruiz, E., Pen˜alva, M. A., and de Co´rdoba, S. R.
(1996) Nat. Genet. 14, 19–24
5. Scriver, C. R., Eisensmith, R. C., Woo, S. L. C., and Kaufman, S. (1997) Annu.
Rev. Genet. 28, 141–165
6. Mitchell, G. A., Lambert, M., and Tanguay, R. M. (1994) in The Metabolic Basis
of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W., and Valle, D.,
eds) pp. 1077–1106, McGraw-Hill Inc., New York
7. La Du, B. N., Zannoni, V. G., Laster, L., and Seegmiller, J. E. (1958) J. Biol.
Chem. 230, 251–260
8. Garrod, A. E. (1902) Lancet 2, 1616–1620
9. Garrod, A. E. (1908) Lancet 2, 73–79
10. Granadino, B., Beltra´n-Valero de Bernabe´, D., Ferna´ndez-Can˜o´n, J. M.,
Pen˜alva, M. A., and Rodrı´guez de Co´rdoba, S. (1997) Genomics 43, 115–122
11. Lindblad, B., Lindstedt, S., and Steen, G. (1977) Proc. Natl. Acad. Sci. U. S. A.
74, 4641–4645
12. Jorquera, R., and Tanguay, R. (1997) Biochem. Biophys. Res. Commun. 232,
42–48
13. Overtuf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C., Finegold, M.,
and Grompe, M. (1996) Nat. Genet. 12, 266–272
14. Berger, R., Michals, K., Galbraeth, J., and Matalon, R. (1988) Pediatr. Res. 23,
328 (abstr.)
15. Knox, W. E., and Edwards, S. W. (1955) J. Biol. Chem. 216, 489–498
16. Edwards, S. W., and Knox, W. E. (1956) J. Biol. Chem. 220, 79–91
17. Seltzer, S. (1973) J. Biol. Chem. 248, 215–222
18. Morrison, W. S., Wong, G., and Seltzer, S. (1976) Biochemistry 15, 4228–4233
19. Clutterbuck, A. J. (1993) in Genetic Maps. Locus Maps of Complex Genomes
(O’Brien, S. J., ed) 6th Ed., Vol. 3, pp. 3.71–3.84, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY
20. Cove, D. J. (1966) Biochim. Biophys. Acta 113, 51–56
21. Ferna´ndez-Can˜o´n, J. M., and Pen˜alva, M. A. (1997) Anal. Biochem. 245,
218–221
22. Espeso, E. A., and Pen˜alva, M. A. (1992) Mol. Microbiol. 6, 1457–1465
23. Tilburn, J., Scazzocchio, C., Taylor, G. G., Zabicky-Zissman, J. H., Lockington,
R. A., and Davies, R. W. (1983) Gene 26, 205–211
24. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
25. Lennon, G. G., Auffray, C., Polymeropoulos, M., and Soares, M. B. (1996)
Genomics 33, 151–152
26. Lee, H. E., and Seltzer, S. (1989) Biochem. Int. 18, 91–97
Fungal and Human Genes for Maleylacetoacetate Isomerase 337
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 18, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
José Manuel Fernández-Cañón and Miguel Angel Peñalva
of Its Human Homologue
Characterization of a Fungal Maleylacetoacetate Isomerase Gene and Identification
doi: 10.1074/jbc.273.1.329
1998, 273:329-337.J. Biol. Chem. 
  
 http://www.jbc.org/content/273/1/329Access the most updated version of this article at 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/273/1/329.full.html#ref-list-1
This article cites 25 references, 7 of which can be accessed free at
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 18, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
